Efficacy of the FAEV regimen.in the treatment of high-risk, drug-resistant gestational trophoblastic tumor

被引:0
|
作者
Wan, Xirun [1 ]
Xiang, Yang [1 ]
Yang, Xiuyu [1 ]
Wu, Yu [1 ]
Liu, Ning [1 ]
Chen, Ling [1 ]
Dong, Ruofan [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing 100730, Peoples R China
关键词
trophoblastic tumor; drug resistance; chemotherapy;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To evaluate the efficacy of the FAEV regimen (floxuridine, actinomycin D, etoposide, vincristine) in the treatment of high-risk, drug-resistant gestational trophoblastic tumor (GTT). STUDY DESIGN: From October 2001 to May 2004, 11 cases of high-risk, drugresistant GTT were treated with the FAEV regimen. All cases were referred to Peking Union Medical College Hospital because of previous failure of chemotherapy. The patients' ages ranged from 21 to 60 (median, 32) years. The International Federation of Gynecologists and Obstetricians score was 7-13 (median, 9). All cases were followed for 15-42 months after FAEV treatment.. RESULTS: Seven cases (63.6%, 7 of 11) were cured by the FAEV regimen. The median course number for serum human chorionic gonadotropin reaching a normal level was 3. Four cases (36%, 4 of 11) showed drug resistance to the FAEV regimen. The major side effect of FAEV regimen is myelosuppression. Granulocyte colony-stimulating factor support was needed after 98.4% (63 of 64) of the courses. CONCLUSION: For high-risk, drug-resistant GTT cases, FAEV regimen could be an effective treatment.
引用
收藏
页码:941 / 944
页数:4
相关论文
共 50 条
  • [1] EMA/CO REGIMEN IN HIGH-RISK GESTATIONAL TROPHOBLASTIC TUMOR (GTT)
    BOLIS, G
    BONAZZI, C
    LANDONI, F
    MANGILI, G
    VERGADORO, F
    ZANABONI, F
    MANGIONI, C
    [J]. GYNECOLOGIC ONCOLOGY, 1988, 31 (03) : 439 - 444
  • [2] MODIFIED BAGSHAWE REGIMEN IN HIGH-RISK GESTATIONAL TROPHOBLASTIC DISEASE
    WONG, LC
    CHOO, YC
    MA, HK
    [J]. GYNECOLOGIC ONCOLOGY, 1986, 23 (01) : 87 - 93
  • [3] Treatment of high-risk gestational trophoblastic tumors
    Wright, JD
    Mutch, DG
    [J]. CLINICAL OBSTETRICS AND GYNECOLOGY, 2003, 46 (03): : 593 - 606
  • [4] Salvage chemotherapy for high-risk gestational trophoblastic tumor
    Matsui, H
    Iitsuka, Y
    Suzuka, K
    Yamazawa, K
    Mitsuhashi, A
    Sekiya, S
    [J]. JOURNAL OF REPRODUCTIVE MEDICINE, 2004, 49 (06) : 438 - 442
  • [5] CISPLATIN, VINBLASTINE, AND BLEOMYCIN COMBINATION IN THE TREATMENT OF RESISTANT HIGH-RISK GESTATIONAL TROPHOBLASTIC TUMORS
    AZAB, M
    DROZ, JP
    THEODORE, C
    WOLFF, JP
    AMIEL, JL
    [J]. CANCER, 1989, 64 (09) : 1829 - 1832
  • [6] Pulmonary resection in the treatment of high-risk gestational trophoblastic neoplasia
    Kanis, M. J.
    Lurain, J. R., III
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 137 : 39 - 40
  • [7] ETOPOSIDE, METHOTREXATE, AND BLEOMYCIN IN DRUG-RESISTANT GESTATIONAL TROPHOBLASTIC DISEASE
    WONG, LC
    CHOO, YC
    MA, HK
    [J]. GYNECOLOGIC ONCOLOGY, 1986, 24 (01) : 51 - 57
  • [8] The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN)
    Newlands, ES
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY, 2003, 17 (06): : 905 - 923
  • [9] The efficacy evaluation of initial chemotherapy for high-risk gestational trophoblastic neoplasm
    Li, Yitong
    Chen, Dan
    Yu, Huihui
    Xia, Rong
    Zhang, Xin
    Zheng, Wei
    [J]. CURRENT PROBLEMS IN CANCER, 2022, 46 (03)
  • [10] Efficacy and safety of the APE (actinomycin D, cisplatin, etoposide) regimen for the management of high-risk gestational trophoblastic neoplasia.
    Lhomme, Catherine
    Even, Caroline
    Duvillard, Pierre
    Pautier, Patricia
    Floquet, Anne
    Kerbrat, Pierre
    Troalen, Frederic
    Rey, Annie
    Balleyguier, Corinne
    Morice, Philippe
    Fizazi, Karim
    Droz, Jean Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)